Management of Metabolic Acidosis in Chronic Kidney Disease

Patient Risk Factors

• Patients with chronic kidney disease (CKD) stages 3-5 are at highest risk of developing non-anion gap metabolic acidosis (NAGMA) when taking oral calcium carbonate 1
• High doses of calcium carbonate, exceeding 2.0 g/day, increase the risk of NAGMA in CKD patients 1

Monitoring and Management

• The Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines recommend maintaining serum total CO₂ levels >22 mEq/L in CKD patients 1
• Regular measurement of serum total CO₂ is recommended based on CKD stage 1
• Total daily calcium intake (dietary + supplements) should not exceed 2.0 g/day in CKD patients to minimize the risk of NAGMA 1
• The maximum recommended total daily calcium intake is 2000 mg/day to prevent hypercalcemia and kidney damage, and patients with chronic kidney disease should limit their calcium intake to avoid soft tissue precipitation, as recommended by the K/DOQI guidelines and the American Journal of Kidney Diseases 2, 1

Treatment Considerations

• For patients with established NAGMA and serum bicarbonate <22 mEq/L, supplemental alkali salts should be given 1
• Correcting acidosis is important, but the American College of Physicians and other guideline societies emphasize that excessive alkali therapy may lead to complications including volume overload and hypocalcemia, thus it is crucial to weigh the benefits and risks 1
• Considering alternative calcium supplements, such as calcium citrate, which has less constipating effects and doesn't contribute to acidosis, may be an option if calcium supplementation is necessary 1

Calcium Supplementation and Constipation

• Calcium carbonate can cause constipation as a common side effect, according to the American College of Gastroenterology 3
• The American Gastroenterological Association recommends MiraLAX (polyethylene glycol) as a first-line treatment for constipation, and Docusate sodium (Colace) as a stool softener for medication-induced constipation 4
• Ensuring adequate fiber intake, particularly psyllium, is suggested as first-line therapy for chronic constipation by the American Gastroenterological Association 4
• Maintaining adequate hydration is crucial when using fiber supplements and calcium products, as recommended by the American College of Gastroenterology 4
• The following table compares different calcium salts:

Laboratory Monitoring

• Serum calcium levels should be monitored, especially in patients with chronic kidney disease, and the total calcium intake (dietary + supplements) should be considered to avoid exceeding 2000 mg/day, as recommended by the American Journal of Kidney Diseases guidelines 2
• Regular monitoring of calcium, parathyroid hormone, magnesium, and creatinine levels is essential for managing hypocalcemia, and serum calcium levels (ionized calcium preferred when available) should be monitored, as recommended by the Endocrine Society and Critical Care 5, 6
• Adequate vitamin D is essential for optimal calcium absorption, and daily vitamin D supplementation is recommended for all patients with hypocalcemia, with a standard dose of 400-1000 IU daily of cholecalciferol or ergocalciferol, according to the Endocrine Society and the American College of Medical Genetics and Genomics 3, 5, 7